Portfolio Planning, Search & Evaluation, Corporate Development, Alliance Management | Consultancy & Fractional Executive Strong track record of value creation and empowering teams with streamlined risk-managed strategies to mobilize in whitespaces of uncharted territories, resulting in significant business growth & multinational exits. MNC, Start-ups, Public Health : Licensing (In-/Out-), Divestitures, Equity/ M&A Specialized in pioneering synergies & emerging technologies at intersection of Pharma & Medtech/Device and Techbio platforms seeking to improve access thru Precision Medicine & Value-Based Care solutions. eg.)Client scope: Oncology Start-up Strategy Women's Health Social Enterprise: Fractional Chief Business Officer - Spearhead impact portfolio expansion to improve equitable access to quality care, empowered leadership w streamlined risk-managed strategy & BD process restructure - first board approved short-list in 14 yrs, w/in 6mo. Multinational Pharma/ Neurology: R&D Pipeline Strategy & Risk management, external innovation AI/RWD & gene therapy pipeline stage gates: psychiatric, genetic neurodevelopment disorders, and ophthalmology, partner with franchise senior scientific exec leadership/General Mgmt in board & investor relations franchise presentation Neurology Microcap: Fractional Strategy Officer/Consultant - Spearheaded organization's first enterprise 1-3-5 strategic plan in 15 yrs, drove workshops & licensing strategy, turn-around initiative's board presentation in partnership with c-suite: resulted in pivot from unprofitable >15 yrs, ~50% turn-over, to pipeline expansion & successful securing multinational exit >3x mkt cap ~1yr later. ---------------------------------------------- Strategic Partnership Ecosystems, R&D Portfolio/Pipeline Planning, Search & Evaluation/Scouting, Roadshows (buy/sell), Due Diligence, Transactions/Contract structuring, Internal/External Negotiation, Alliance Management, Process Development, Advisor/Coach

(acquired by Zevra Therapeutics) Leadership for pipeline expansion (buy-side in-license/M&A ): Leveraged network to identify high ROI market ready pipeline assets, potential AI/ML joint venture in rare disease repurposing, and globally reknown academic hospital system collaboration in rare disorder (investments discontinued upon FDA CRL for Edsivo, Acer’s former lead compound.) Preliminary differentiation strategy & business plan for Olpruva (Acer's first FDA approved/launched product - prior to Zevra acquisition)

(acquired by PTC Therapeutics) Rare Neuro/Metabolic disorders and Aging/Longevity therapeutics with data science-driven medtech portfolio, driven by mitigating mechanisms of mitochondrial dysfunction and other breakdowns in biological energy.

Oncology/Immuno-Oncology and Autoimmune Pharmaceutical Companion Diagnostic Alliances, across NGS, qPCR, immunoassay platforms. Recipient of 3 management awards.

Business Development and Alliance Management for Public-Private Sector strategic alliance(s) in consortium of Fortune 500 Diagnostic organizations for GSK Complementary Diagnostic Test development for G6PD enzyme deficiency to address growing unmet need for accessibility to safe radical cure of P.vivax Malaria, in underserved endemic regions of Southeast Asia. Drove momentum for a previously stalled & undervalued program with no private sector interest toward receiving multiple termsheets, with incremental funding, and became one of the largest funded public/private Diagnostic programs for Path. Target Partner Strategy and Deployment - Drove traction of partnering consortium engagement and selection with matrix team, Market Intelligence & Value Proposition, TPP Development, Art Direction & Content development of Dossiers/Marketing Collateral, Roadshow Lead, Internal/External negotiations, Public-Private Agreements, Due Diligence, International KOL Advisory Panel, White Paper/Grant submission - resulting in one of the largest diagnostic program grants at PATH by Bill and Melinda Gates Foundation and DfID (Dept for International Development).

Social enterprise to optimize product design, marketing and distribution for sustainable trades and artisan crafts from regions of endangered species, in support of alternate livelihoods at intersection of global wildlife conservation and poverty alleviation objectives. Business model transitioned to NYC Design firm social responsibility initiative.

Developed and executed worldwide partnering strategy transformation for Phase I Infectious Disease device/drug combination (gram negative Pneumonia for mechanically ventilated ICU patients) resulting in Bayer deal and culminating in Novartis acquisition, with aggregate value up to $285M. Led target partnering playbook, value proposition, art direction & content of presentations/marketing collateral, alliance structure, internal and external negotiation, and due diligence, leading traction of 40+ member matrix team and roadshow. Developed initial strategic roadmap for prospective partners and messaging for PEG-Naloxol (now Naloxegol), ultimately out licensed to Astra Zeneca valued up to $1.5B.

Structured, negotiated, and managed execution of 3 Oncology collaborations covering co-development, licensing, and equity investments in molecular imaging (theranostics/radiopharmaceuticals), with up to 67%+ greater deal value. Assessments on M&A start-up investments’ value propositions and valuations, with Corporate Ventures/M&A - bridging pharma & nuclear medicine imaging & radiation treatment planning software. Managed strategic planning/portfolio roadmap process for Nuclear Medicine business units (Radiation Oncology/Treatment Planning, Molecular Imaging, and SPECT), driving portfolio decisions to closure. Liaison amongst Philips corporate business development and general management.

Pioneering Non-Invasive Protein and Peptide drug delivery R&D portfolio strategy/upstream strategic marketing, business dvelopment strategy & business planning

Various roles: Global Business Development for investments in Inflammation, CV, Oncology assets, Ag & Pharma Research Platforms, Chief of Staff to General Manager of Middle-East/North Africa region overseeing Business Development, Operational and Marketing Management for 12 countries, UK Product Manager over Medical Education for Celebrex/Patient Partners across 40 rheumatology centers, US Business Development

Managed and developed marketing campaigns to enhance brand reach and engagement.

Implemented SEO and content strategies to improve online visibility.